Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial-Reference-Cited by-同舟云学术

Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial

Published:2001-08 Issue:8 Volume:23 Page:1166-1179
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Elliott William J.,Calhoun David A.,DeLucca Paul T.,Gazdick Lisa P.,Kerns Dawn E.,Zeldin Robert K.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference29 articles.

1. 1999 World Health Organization—International Society of Hypertension guidelines for the management of hypertension;Blood Press Suppl,1999

2. Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors;Goldberg;J Hypertens,1995

3. Losartan potassium: A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension;Goa;Drugs,1996

4. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension;Markham;Drugs,1997

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibiting the cancer cell growth by maleopimarate amino imide bis-tetrazoles synthesized via the azido-Ugi reaction;Mendeleev Communications;2024-07

2. Effects of the DASH diet and losartan on serum urate among adults with hypertension: Results of a randomized trial;The Journal of Clinical Hypertension;2023-09-11

3. Prevalence of Hyperuricemia and Associated Factors Among Type 2 Diabetic Patients in Jordan;International Journal of General Medicine;2022-08

4. Losartan and Eprosartan Induce a Similar Effect on the Acute Rise in Serum Uric Acid Concentration after an Oral Fructose Load in Patients with Metabolic Syndrome;Journal of the Renin-Angiotensin-Aldosterone System;2021-08-25

5. Effects of angiotensin II receptor blockers on serum potassium level and hyperkalemia risk: retrospective single-centre analysis;European Journal of Hospital Pharmacy;2021-06-28